Summary
Intuitive Surgical Inc. (ISRG) reported its financial results for the quarter and six months ended June 30, 2022. Total revenue for the quarter increased by 4% year-over-year to $1.52 billion, driven by a 12% increase in instruments and accessories revenue, largely due to a 14% rise in da Vinci procedures. However, systems revenue saw a 15% decline, impacted by fewer system placements and supply chain challenges. The company's installed base of da Vinci Surgical Systems grew by 13% year-over-year to 7,135 systems. For the six-month period, total revenue grew by 9% to $3.0 billion, with instruments and accessories revenue up 14% and service revenue up 12%, while systems revenue remained flat. The company continues to invest significantly in research and development, with R&D expenses increasing by 30% year-over-year for the six-month period, indicating a focus on future innovation. Despite revenue growth, operating income decreased by 22% for the quarter due to increased operating expenses, including higher selling, general, and administrative costs and research and development expenses.
Financial Highlights
45 data points| Revenue | $1.52B |
| Cost of Revenue | $498.80M |
| Gross Profit | $1.02B |
| R&D Expenses | $207.30M |
| SG&A Expenses | $418.40M |
| Operating Expenses | $625.70M |
| Operating Income | $397.60M |
| Net Income | $307.80M |
| EPS (Basic) | $0.86 |
| EPS (Diluted) | $0.85 |
| Shares Outstanding (Basic) | 358.10M |
| Shares Outstanding (Diluted) | 363.90M |
Key Highlights
- 1Total revenue for the three months ended June 30, 2022, increased 4% to $1.52 billion, driven by strong performance in instruments, accessories, and services.
- 2Da Vinci procedures increased by 14% year-over-year in the second quarter of 2022, reaching approximately 465,000, indicating continued adoption and utilization of the da Vinci Surgical System.
- 3Systems revenue saw a notable decrease of 15% to $375 million in the second quarter, attributed to a 15% decline in da Vinci Surgical System placements and challenges in the supply chain.
- 4The company's installed base of da Vinci Surgical Systems grew 13% year-over-year to 7,135 systems as of June 30, 2022, demonstrating ongoing expansion.
- 5Operating income decreased by 22% to $398 million in the second quarter, primarily due to a significant increase in operating expenses, including R&D and SG&A, as the company continues to invest in growth initiatives.
- 6The company repurchased approximately $607 million of its common stock during the first six months of 2022, signaling a commitment to returning capital to shareholders.
- 7While overall revenue shows growth, the company highlighted ongoing supply chain challenges and macroeconomic pressures, such as inflation and rising interest rates, impacting hospital capital spending and potentially future system demand.